Abstract:Background The most common type of kidney cancer that easily metastasizes is clear cell renal cell carcinoma (ccRCC). The expression levels of hyaluronan-mediated motility receptor (HMMR) in many tumor types are significantly enhanced. HMMR is closely associated with tumor-related progression, treatment resistance, and discouraging prognosis, has yet to be fully investigated in terms of its expression patterns and molecular mechanisms of action in ccRCC. Further research is imperative to elucidate these aspects. Methods We used The Cancer Genome Atlas (TCGA) database to preliminarily investigate HMMR expression and function in ccRCC. We assessed the differential expression level of HMMR between ccRCC cancerous tissues and their matched non-tumor tissues. Subsequently, a series of in vivo and in vitro experiments were designed to elucidate the biological function of HMMR in ccRCC, including Transwell migration assays, CCK-8 assays, clone formation assays and subcutaneous xenograft experiments in nude mice. Through bioinformatics analysis, we identified potential microRNAs (miRNAs) that may regulate HMMR, as well as the possible signaling pathways involved. Finally, we conducted a series of cellular functional experiments to validate our hypotheses regarding the HMMR axis. Results HMMR expression was observably up-regulated in tumor tissues of ccRCC patients, and elevated HMMR expression level showed a strong correlation with ccRCC progression and adverse prognoses of patients. Knocking down HMMR inhibited the proliferative and migratory abilities of ccRCC cells, while its overexpression amplified these oncogenic properties. In nude mouse model, reduced HMMR expression inhibited ccRCC tumor proliferation in vivo. Furthermore, overexpression of an upstream transcriptional regulator, miR-9-5p, effectively downregulated HMMR expression and thus impeded ccRCC cells proliferation and migration. In addition, HMMR might influence ccRCC growth via the Epithelial-Mesenchymal Transition (EMT) pathway and the Janus Kinase1/Signal Transducer and Activator of Transcription1 (JAK1/STAT1) pathway. Conclusions HMMR is overexpressed in ccRCC, and there is a significant link between high HMMR expression and tumor progression, as well as poor patient prognosis. Specifically, HMMR could be targeted and inhibited by miR-9-5p and might modulate the tumorigenesis and progression of ccRCC through both EMT and JAK1/STAT1 signaling pathway.

Epigenetic activation of RBM15 promotes clear cell renal cell carcinoma growth, metastasis and macrophage infiltration by regulating the m6A modification of CXCL11

RNA M5c Methylation Orchestrates BLCA Progression Via Macrophage Reprogramming

Mir-9-5p/hmmr Regulates the Tumorigenesis and Progression of Clear Cell Renal Cell Carcinoma Through EMT and JAK1/STAT1 Signaling Pathway

RBM15 Promotes Hepatocellular Carcinoma Progression by Regulating N6-methyladenosine Modification of YES1 Mrna in an IGF2BP1-dependent Manner.

RNA methylase RBM15 facilitates malignant progression of colorectal cancer through regulating E2F2 in an m6A modification‐dependent manner

Establishment of a Risk Signature Based on M6a RNA Methylation Regulators That Predicts Poor Prognosis in Renal Cell Carcinoma

DMDRMR -Mediated Regulation of m 6 A-Modified CDK4 by m 6 A Reader IGF2BP3 Drives ccRCC Progression

N6-methyladenosine RNA Methylation Regulators Participate in Malignant Progression and Have Prognostic Value in Clear Cell Renal Cell Carcinoma

DMDRMR-Mediated Regulation of M6a-Modified CDK4 by M6a Reader IGF2BP3 Drives Ccrcc Progression.

Knockdown of RBM15 inhibits tumor progression and the JAK-STAT signaling pathway in cervical cancer

RBM15 facilitates laryngeal squamous cell carcinoma progression by regulating TMBIM6 stability through IGF2BP3 dependent

RBM15 condensates modulate m 6 A modification of STYK1 to promote tumorigenesis

RBM15 Knockdown Impairs the Malignancy of Cervical Cancer by Mediating m6A Modification of Decorin

m6A Methylation Patterns and Tumor Microenvironment Infiltration Characterization in Clear-Cell Renal Cell Carcinoma

Comprehensive analysis of m6A methylome and transcriptome by Nanopore sequencing in clear cell renal carcinoma

Single-cell and spatial transcriptomics reveal 5-methylcytosine RNA methylation regulators immunologically reprograms tumor microenvironment characterizations, immunotherapy response and precision treatment of clear cell renal cell carcinoma

EGR2-mediated regulation of m6A reader IGF2BP proteins drive RCC tumorigenesis and metastasis via enhancing S1PR3 mRNA stabilization

Downregulated METTL14 accumulates BPTF that reinforces super-enhancers and distal lung metastasis via glycolytic reprogramming in renal cell carcinoma

Comprehensive investigation of malignant epithelial cell-related genes in clear cell renal cell carcinoma: development of a prognostic signature and exploration of tumor microenvironment interactions

METTL14-mediated Lnc-LSG1 M6a Modification Inhibits Clear Cell Renal Cell Carcinoma Metastasis Via Regulating ESRP2 Ubiquitination

RBM15B Promotes Prostate Cancer Cell Proliferation via PCNA m6A Modification